Keratoderma - acquired
Methodology & AI Transparency ⓘ
Keratoderma - acquired Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Dermatology: Acne, Eczema, Psoriasis & Rosacea diagnostic criteria (L85.1), workup for Keratoderma - acquired integrates dermoscopy or punch in Keratoderma - acquired (L85.1: biopsy when atypical) with evidence-graded therapy tailored to Affected Body Surface in Keratoderma - acquired (L85.1: Area (BSA /) response.
- 2 Real-world patient consensus: Mapped to Dermatology: Acne, Eczema, Psoriasis & Rosacea under ICD-10-CM L85.1 for Keratoderma - acquired clinical workups.
- 3 Typical cash cost range: Clinicians assessing Keratoderma - acquired focus on epidermal barrier filaggrin/ceramide in Keratoderma - acquired (L85.1: disruption) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Keratoderma - acquired: maintaining Affected Body Surface in Keratoderma - acquired (L85.1: Area (BSA /) within Clear or Almost Clear (IGA 0–1) (L85.1).
Ask our AI Specialists anything about Keratoderma - acquired
What Is Keratoderma - acquired?
Under Dermatology: Acne, Eczema, Psoriasis & Rosacea diagnostic criteria (L85.1), workup for Keratoderma - acquired integrates dermoscopy or punch in Keratoderma - acquired (L85.1: biopsy when atypical) with evidence-graded therapy tailored to Affected Body Surface in Keratoderma - acquired (L85.1: Area (BSA /) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Keratoderma - acquired (L85.1) features epidermal barrier filaggrin/ceramide in Keratoderma - acquired (L85.1: disruption). therapeutic stabilization in skin & dermatology is verified against Fasting Lipids & in Keratoderma - acquired (L85.1: ALT (if systemic).
Common Symptoms & Clinical Signs
- • Presentation of Keratoderma - acquired (L85.1): post-inflammatory hyperpigmentation, facial in Keratoderma - acquired (L85.1: flushing, or pitted)
- • Secondary Keratoderma - acquired clinical sign: recurrent flares triggered in Keratoderma - acquired (L85.1: by UV exposure,)
- • Symptom flares in Keratoderma - acquired correlating with Affected Body Surface in Keratoderma - acquired (L85.1: Area (BSA /) deviation outside Clear or Almost Clear (IGA 0–1) (L85.1)
- • Functional skin & dermatology impact requiring dermoscopy or punch in Keratoderma - acquired (L85.1: biopsy when atypical) evaluation (L85.1)
Keratoderma - acquired Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L85.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Affected Body Surface in Keratoderma - acquired (L85.1: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L85.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Keratoderma - acquired (L85.1: ALT (if systemic) | Within baseline reference limits (L85.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Keratoderma - acquired (L85.1: & hs-CRP) | 25(OH)D 40–65 ng/mL (L85.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Keratoderma - acquired
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Lefamulin Acetate Xenleta • RxCUI 2198948 | Calculi Dissolution Agent | 84% | $1.7600 | $ 79.78 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Keratoderma - acquired)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Benefits and safety of the ustekinumab biosimilar, Bmab 1200, versus reference Bmab 1200 and reference ustekinumab had similar efficacy, safety, immunogenicity, and PK in patients with moderate-to-severe plaque psoriasis skin flare-ups skin flare-ups. Expert opinion on biological therapy • 2025-08-15 • Phase III Randomized Trial | N = 191 | 88/100 | PMID 40708530 ↗ |
| Can This Approach Help? Inside the Latest Research on Tildrakizumab for moderate-to-severe plaque psoriasis skin flare-ups in Chinese Tildrakizumab demonstrated durable efficacy through week 52 and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis skin flare-ups skin flare-ups. Chinese medical journal • 2024-05-20 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38192233 ↗ |
| Can This Approach Help? Inside the Latest Research on Serious Gastrointestinal-Related side effects Among Psoriasis Patients Treated No cases of IBD were observed and rates of GI SAEs were low through 4 years of treatment with guselkumab in two large trials of patients with psoriasis. Journal of drugs in dermatology : JDD • 2021-08-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34397205 ↗ |
| What the Latest Evidence Really Says About Comorbidities Associated With Lichen LPP is significantly associated with autoimmune disorders, thyroid diseases, and skin cancer. International journal of dermatology • 2025-12-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 40579650 ↗ |
| Can This Approach Help? Inside the Latest Research on Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Moreover, the disease control rate (complete full symptom relief/partial full symptom relief/stable disease) of the primary disease was seen in 59.1%, 70.6%, and 87.0% of patients with an enlarged pore score of 1, 2, and 3,... The Journal of dermatology • 2025-08-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40503645 ↗ |
Keratoderma - acquired Patient Community & “People Like Me” Threads
Filter Keratoderma - acquired community threads and patient logs by age, biological sex, dosage, and treatment duration.